Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by StockNews.com

Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Other research analysts also recently issued research reports about the company. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, Truist Financial reissued a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.25.

Marinus Pharmaceuticals Trading Up 6.0 %

Shares of MRNS opened at $1.60 on Wednesday. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The firm has a market capitalization of $87.89 million, a P/E ratio of -0.61 and a beta of 1.13. The firm’s 50-day moving average is $1.37 and its two-hundred day moving average is $2.92.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter in the prior year, the company earned ($0.61) EPS. On average, research analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MRNS. Hussman Strategic Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the period. Point72 DIFC Ltd acquired a new position in Marinus Pharmaceuticals in the second quarter valued at $28,000. SG Americas Securities LLC purchased a new position in Marinus Pharmaceuticals during the second quarter worth about $34,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Marinus Pharmaceuticals during the first quarter worth about $384,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.